# Plasma Adsorption in Patients With Confirmed COVID-19

> **NCT04358003** · NA · COMPLETED · sponsor: **Marker Therapeutics AG** · enrollment: 107 (actual)

## Conditions studied

- Respiratory Failure
- ARDS

## Interventions

- **DEVICE:** Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)

## Key facts

- **NCT ID:** NCT04358003
- **Lead sponsor:** Marker Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-20
- **Primary completion:** 2021-11-26
- **Final completion:** 2022-04-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358003, "Plasma Adsorption in Patients With Confirmed COVID-19". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04358003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*